SynthesisBMC cancer2025
Incidence and risk factors of hypothyroidism in patients with hematological malignancies compared to healthy population: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPrevious literature has reported hypothyroidism as a long-term endocrine complication in hematological malignancy (HM) patients. Nevertheless, there is a lack of a comprehensive study determining the incidence of hypothyroidism in this population. We aimed to systematically investigate the incidence compared to the healthy population and determine the significant risk factors. MATERIALS AND
methodsWe conducted a systematic search of PubMed, Scopus, and Web of Science for studies published up to April 2025. Eligible studies were analyzed using a random-effects model to estimate pooled incidence rates. Heterogeneity across studies was assessed using the I² statistic. Subgroup analyses were performed to explore the impact of specific risk factors, and publication bias was evaluated using funnel plots and Egger’s test.
resultsThis study included 32 studies and revealed a significantly higher incidence of hypothyroidism in HM patients with pooled risk estimates of 5.47 (95% CI: 3.11; 9.61, P-value < 0.0001), with the highest pooled risk estimates in patients with lymphoma with an HR of 8.62 (95% CI: 3.79; 19.57, P-value < 0.0001). Additionally, several significant risk factors, such as female sex, chemotherapy, radiotherapy (RT), total body irradiation (TBI), and white ethnicity, have been identified as significantly associated with hypothyroidism incidence. In contrast, no significant correlation between cGVHD, alkylating agent, cyclophosphamide, donor source, nodular sclerosing, the stage, and stem cell source and incidence of hypothyroidism was observed.
conclusionThis meta-analysis demonstrates that patients with HMs are at significantly increased risk for developing hypothyroidism. These findings highlight the importance of early screening and endocrine management in high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.